|11.225 -0.275 (-2.39%)||12-05 11:03|
|Targets||6-month :||14.02||1-year :||15.48|
|Resists||First :||12||Second :||13.25|
|Supports||First :||9.98||Second :||8.3|
|MAs||MA(5) :||11.52||MA(20) :||11.32|
|MA(100) :||14.56||MA(250) :||14.67|
|MACD||MACD :||-0.3||Signal :||-0.4|
|%K %D||K(14,3) :||62.9||D(3) :||57.9|
|52-week||High :||24.79||Low :||3.63|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELVN ] has closed below upper band by 37.7%. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||11.88 - 11.94||11.94 - 11.99|
|Low:||11.08 - 11.14||11.14 - 11.19|
|Close:||11.41 - 11.51||11.51 - 11.59|
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||41 (M)|
|Shares Float||11 (M)|
|Held by Insiders||7 (%)|
|Held by Institutions||85.9 (%)|
|Shares Short||5,220 (K)|
|Shares Short P.Month||5,100 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||6.34|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-23.9 %|
|Return on Equity (ttm)||-36 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-57 (M)|
|Levered Free Cash Flow||-31 (M)|
|Price to Book value||1.79|
|Price to Sales||0|
|Price to Cash Flow||-8.26|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|